Landos Biopharma, Inc.
NASDAQ: LABP0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Gregory Oakes
- Employees
- 19
- Headquarters
- Blacksburg, United States
- IPO year
- 2021
- Market cap
- $71.7M
- Website
- https://landosbiopharma.com
Loading LABP…
Loading profile data…Frequently asked questions about LABP
What does Landos Biopharma, Inc. (LABP) do?
Landos Biopharma, Inc. is a biopharmaceutical firm operating in the clinical stage, focused on the discovery and development of innovative oral therapies aimed at treating a range of autoimmune disorders. Their leading clinical-stage candidate, omilancor, is an oral, gut-specific therapeutic designed to modulate lanthionine synthetase C-like pro...
Where does LABP trade?
Landos Biopharma, Inc. (LABP) trades on the NASDAQ Global Market.
What sector is LABP in?
Landos Biopharma, Inc. (LABP) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Landos Biopharma, Inc.?
Gregory Oakes is the chief executive officer of Landos Biopharma, Inc. (LABP).
Where is Landos Biopharma, Inc. headquartered?
Landos Biopharma, Inc. is headquartered in United States.
Does LABP pay a dividend?
Landos Biopharma, Inc. (LABP) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did LABP go public?
Landos Biopharma, Inc. (LABP) completed its initial public offering in 2021.